XML 39 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
May 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]                
Revenue $ 159,000 $ 1,498,000 $ 525,000 $ 17,953,000        
Upfront cash payment received 55,552,000   55,552,000   $ 52,096,000 $ 81,572,000    
Collaboration Agreement with AstraZeneca                
Disaggregation of Revenue [Line Items]                
Revenue     500,000 16,300,000        
Upfront cash payment received             $ 40,000,000 $ 20,000,000
Milestone payments received     0 10,000,000 $ 10,000,000      
Research Collaboration Income                
Disaggregation of Revenue [Line Items]                
Revenue 159,000 1,496,000 525,000 17,808,000        
Royalty Income                
Disaggregation of Revenue [Line Items]                
Revenue $ 0 $ 2,000 $ 0 $ 145,000